Krka, d. d., Novo mesto
Slovenia · SI0031102120 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Fair
- Revenue +5.7% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Good
- It earned 16% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Good
- Equity is 79% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | €1.6B | €1.7B | €1.8B | €1.9B |
| Operating profit | €355M | €381M | €400M | €428M |
| Net profit to shareholders | €309M | €363M | €314M | €357M |
| Earnings per share | €9.92 | €11.69 | €10.14 | €11.60 |
| Cash from operations | €386M | €468M | €227M | €361M |
| Capital spending | €66M | €88M | €130M | €108M |
| Cash | €160M | €519M | €174M | €345M |
| Total assets | €2.5B | €2.7B | €2.8B | €2.8B |
| Equity | €1.9B | €2.1B | €2.2B | €2.2B |
What they do
In the company's own words, from the annual report.
The Krka Group develops, produces, markets, and sells human health products (prescription pharmaceuticals and non- prescription products), animal health products, and health resort and tourist services.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.